Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry 7-Year Interim Results

Juvenile Idiopathic Arthritis

Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study

Arthritis Rheumatol.

Brunner HI, Tzaribachev N, Vega-Cornejo G, Louw I, Berman A, Penadés IC, Antón J, Ávila-Zapata F, Cuttica R, Horneff G, Foeldvari I, Keltsev V, Kingsbury DJ, Viola DO, Joos R, Lauwerys B, Paz Gastañaga ME, Rama ME, Wouters C, Bohnsack J Breedt J, Fischbach M, Lutz T, Minden K, Miraval T, Ally MM, Rubio-Pérez N, Solau Gervais E, van Zyl R, Li X, Nys M, Wong R, Banerjee S, Lovell DJ, Martini A, Ruperto N

doi: 10.1002/art.40466.

Juvenile Idiopathic Arthritis

Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial

J Rheumatol.

Bharucha KN, Brunner HI, Calvo Penadés I, Nikishina I, Rubio-Pérez N, Oliveira S, Kobusinska K, Schmeling H, Sztajnbok F, Weller-Heinemann F, Zholobova E, Zulian F, Allen R, Chaitow J, Frane J, Wells C, Ruperto N, De Benedetti F, Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group

doi: 10.3899/jrheum.170326.

Juvenile Idiopathic Arthritis

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

Ann Rheum Dis.

Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, Horneff G, Kasapcopur O, Schneider R, Anton J, Barash J, Berner R, Corona F, Cuttica R, Fouillet-Desjonqueres M, Fischbach M, Foster HE, Foell D, Radominski SC, Ramanan AV, Trauzeddel R, Unsal E, Levy J, Vritzali E, Martini A, Lovell DJ

doi: 10.1136/annrheumdis-2018-213150.

Juvenile Idiopathic Arthritis

Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis

N Engl J Med.

Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, Hardwick B, Hickey H, Hughes D, Woo P, Benton D, Edelsten C, Beresford MW; SYCAMORE Study Group

doi: 10.1056/NEJMoa1614160.

Juvenile Idiopathic Arthritis

Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study

Rheumatology (Oxford).

Heiligenhaus A, Klotsche J, Tappeiner C, Sengler C, Niewerth M, Liedmann I, Hoeft S, Walscheid K, Lavric M, Foell D, Minden K

doi: 10.1093/rheumatology/key406.

Autoimmune DiseaseJuvenile Idiopathic Arthritis

Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis

Clin Rheumatol.

Correll CK, Bullock DR, Cafferty RM, Vehe RK

doi: 10.1007/s10067-017-3890-4.

Juvenile Idiopathic Arthritis

Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis

Rheumatology (Oxford).

Grönlund MM, Remes-Pakarinen T, Kröger L, Markula-Patjas K, Backström M, Putto-Laurila A, Aalto K, Vähäsalo P

doi: 10.1093/rheumatology/kez291.

Rheumatoid Arthritis

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry

Rheumatol Ther.

Pappas DA, Kremer JM, Griffith J, Reed G, Salim B, Karki C, Garg V

doi: 10.1007/s40744-017-0077-z.

Juvenile Idiopathic Arthritis

Pregnancy outcomes in DMARD-exposed patients with juvenile idiopathic arthritis-results from a JIA biologic registry

Rheumatology (Oxford).

Drechsel P, Stüdemann K, Niewerth M, Horneff G, Fischer-Betz R, Seipelt E, Spähtling-Mestekemper S, Aries P, Zink A, Klotsche J, Minden K

doi: 10.1093/rheumatology/kez309.

Related content

Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study

Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis

Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study

Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis

Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry

Pregnancy outcomes in DMARD-exposed patients with juvenile idiopathic arthritis-results from a JIA biologic registry